We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GENEART Supports the UK HIV Vaccine Consortium in Developing a DNA Vaccine Candidate against HIV

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "GENEART Supports the UK HIV Vaccine Consortium in Developing a DNA Vaccine Candidate against HIV"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:
GENEART AG announces being awarded a contract for the design and production of two DNA vaccine candidates against HIV by the UK HVC. The genes (blueprints for virus proteins), optimized and customized by GENEART, are to be used as basis for clinical studies.

Two gene constructs, developed by GENEART in cooperation with the Institute of Medical Microbiology and Hygiene at the University of Regensburg, are currently being evaluated at Clinical Phase I/II under the umbrella of the European research syndicate EuroVacc, since Phase I results were promising.

The genes ordered by the UK HVC are based on a different HIV isolate but rest on the same concept as the gene constructs already used in clinical studies. Blueprints of selected proteins of the HIV virus are modified using GENEART's proprietary GeneOptimizer® Software such that they can be produced with maximal yield and therefore triggering an optimal immune response but at the same time losing their toxic capacity, thus contributing to an increased safety profile.

GENEART will not only provide the respective genes, but will in addition - as an extension of the value chain - analyze and ensure the producibility of the resulting proteins in cell cultures (Expression Proof).

The UK HVC does not only benefit from the rational design of the respective genes or virus proteins but also from a production in accordance with DIN EN ISO 9001:2000 as well as a documentation of the production process. Thereby, GENEART provides ideal conditions for the subsequent approval process.

"This order shows once again how we established both gene design and gene synthesis as the gold standard for the development of vaccines. Customers benefit from optimal properties with respect to immune response and safety due to maximal design flexibility during the development of vaccines", said Prof. Dr. Ralf Wagner, CEO and CSO of GENEART.